Human-Derived Physiological Heat Shock Protein 27 Complex Protects Brain after Focal Cerebral Ischemia in Mice

Shinichiro Teramoto1,2,* , Hideki Shimura3,4,*, Ryota Tanaka1,3,4, Yoshiaki Shimada1, Nobukazu Miyamoto1, Hajime Arai2, Takao Urabe3, Nobutaka Hattori1*

1 Department of Neurology, Juntendo University School of Medicine, Tokyo, Japan, 2 Department of Neurosurgery, Juntendo University School of Medicine, Tokyo, Japan, 3 Department of Neurology at Juntendo University Urayasu Hospital, Juntendo University School of Medicine, Chiba, Japan, 4 Institute for Environment and Gender-Specific Medicine, Juntendo University Graduate School of Medicine, Chiba, Japan

Abstract

Although challenging, neuroprotective therapies for ischemic stroke remain an interesting strategy for countering ischemic injury and suppressing brain tissue damage. Among potential neuroprotective molecules, heat shock protein 27 (HSP27) is a strong cell death suppressor. To assess the neuroprotective effects of HSP27 in a mouse model of transient middle cerebral artery occlusion, we purified a "physiological" HSP27 (hHSP27) from normal human lymphocytes. hHSP27 differed from recombinant HSP27 in that it formed dimeric, tetrameric, and multimeric complexes, was phosphorylated, and contained small amounts of αβ-crystallin and HSP20. Mice received intravenous injections of hHSP27 following focal cerebral ischemia. Infarct volume, neurological deficit scores, physiological parameters, and immunohistochemical analyses were evaluated 24 h after reperfusion. Intravenous injections of hHSP27 1 h after reperfusion significantly reduced infarct size and improved neurological deficits. Injected hHSP27 was localized in neurons on the ischemic side of the brain. hHSP27 suppressed neuronal cell death resulting from cytochrome c-mediated caspase activation, oxidative stress, and inflammatory responses. Recombinant HSP27 (rHSP27), which was artificially expressed and purified from Escherichia coli, and dephosphorylated hHSP27 did not have brain protective effects, suggesting that the phosphorylation of HSP27 may be important for neuroprotection after ischemic insults. The present study suggests that hHSP27 with posttranslational modifications provided neuroprotection against ischemia/reperfusion injury and that the protection was mediated through the inhibition of apoptosis, oxidative stress, and inflammation. Intravenously injected human HSP27 should be explored for the treatment of acute ischemic strokes.

Introduction

Ischemic brain injury is a major health problem. Despite numerous clinical trials, many neuroprotective therapies have failed [1]. Protecting brain tissue from ischemic injury is a considerable challenge in stroke treatment strategies. However, not all brain cells die immediately after an ischemic event. Surrounding the core of severely and rapidly injured brain tissue, cell death spreads slowly in a heterogeneous region called the penumbra, which is salvageable [2]. While numerous preclinical studies demonstrated that neuroprotective strategies significantly reduce the ischemic penumbra [3], many strategies have failed in clinical trials for several reasons [4]. For example, reactions to compounds and peptides may differ between test animals and humans. We hypothesized that endogenous human proteins should not evoke adverse reactions and might be ideal neuroprotective molecules for treating ischemic stroke patients.

Neuronal injury after cerebral ischemia involves a complex series of cellular stresses, including oxidative stress, inflammation, and apoptosis, all of which can lead to cell death [5,6]. Thus, multifunctional molecules that suppress cell death, are anti-apoptotic, and scavenge free radicals are ideal neuroprotective agents. Heat shock protein 27 (HSP27) provides robust cellular protection, is an adenosine triphosphate-independent chaperone, a strong cell death suppressor. To assess the neuroprotective effects of HSP27 in a mouse model of transient middle cerebral artery occlusion, we purified a “physiological” HSP27 (hHSP27) from normal human lymphocytes. hHSP27 differed from recombinant HSP27 in that it formed dimeric, tetrameric, and multimeric complexes, was phosphorylated, and contained small amounts of αβ-crystallin and HSP20. Mice received intravenous injections of hHSP27 following focal cerebral ischemia. Infarct volume, neurological deficit scores, physiological parameters, and immunohistochemical analyses were evaluated 24 h after reperfusion. Intravenous injections of hHSP27 1 h after reperfusion significantly reduced infarct size and improved neurological deficits. Injected hHSP27 was localized in neurons on the ischemic side of the brain. hHSP27 suppressed neuronal cell death resulting from cytochrome c-mediated caspase activation, oxidative stress, and inflammatory responses. Recombinant HSP27 (rHSP27), which was artificially expressed and purified from Escherichia coli, and dephosphorylated hHSP27 did not have brain protective effects, suggesting that the phosphorylation of HSP27 may be important for neuroprotection after ischemic insults. The present study suggests that hHSP27 with posttranslational modifications provided neuroprotection against ischemia/reperfusion injury and that the protection was mediated through the inhibition of apoptosis, oxidative stress, and inflammation. Intravenously injected human HSP27 should be explored for the treatment of acute ischemic strokes.

These authors contributed equally to this work.

Citation: Teramoto S, Shimura H, Tanaka R, Shimada Y, Miyamoto N, et al. (2013) Human-Derived Physiological Heat Shock Protein 27 Complex Protects Brain after Focal Cerebral Ischemia in Mice. PLoS ONE 8(6): e66001. doi:10.1371/journal.pone.0066001

Editor: Thiruma V. Arumugam, University of Queensland, Australia

Received February 27, 2013; Accepted April 30, 2013; Published June 13, 2013

Copyright: © 2013 Teramoto et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This study was partly supported by a High Technology Research Center grant and a Grant-in-Aid for exploratory research from the Ministry of Education, Culture, Sports, Science and Technology in Japan and by a Grant-in-Aid for Scientific Research from the Japan Society for the Promotion of Science (21700395, H. Shimura; 21500338, T. Urabe) and from the Takeda Science Foundation (H. Shimura). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: shishimura@juntendo-urayasu.jp (HS); nhhattori@juntendo.ac.jp (NH)

These authors contributed equally to this work.
Alzheimer disease [15,16], and in the SOD1G93A model of amyotrophic lateral sclerosis [17]. HSP27-transgenic mice exhibit reduced infarcts after transient cerebral ischemia [18], and viral delivery of HSP27 and intraperitoneal injection of PEP1-HSP27, but not HSP27 recombinant protein, into ischemic animal models are also protective [19,20]. Finally, endogenous induction of HSP27 was observed in ischemia-surviving cells [21] and in ischemic preconditioning models [22,23], suggesting that HSP27 is associated with cellular survival following cerebral ischemia. Phosphorylation and oligomerization of HSP27 are both essential for mediating neuroprotection against ischemic neuronal injury in HSP27 transgenic mouse models [24]. All of which suggest that HSP27 is a strong candidate molecule for brain protection against ischemic neuronal injury, and demonstrated that it attenuated ischemic brain damage in a mouse model of transient middle cerebral artery occlusion (MCAO).

Materials and Methods

HSP27 Antibodies

We generated 2 anti-HSP27 rabbit polyclonal antibodies: anti-HSP27-N1 against the 15-mer sequence MTERRVPSLLRPGC at the N-terminal domain of human HSP27 and anti-HSP27-C1 against the 15-mer sequence CGGPEAAKSDETAAK at the C-terminal domain of human HSP27.

Human Physiological HSP27 Preparation

Heparinized human peripheral blood (40 mL) was obtained from two normal control subjects and separated by density gradient centrifugation in Lympholyte-H (Cedarlane Laboratories Ltd., Hornby, Ontario, Canada) according to the manufacturer’s instructions. Cells were lysed in lysis buffer (50 mmol/L Tris-HCl, pH 7.5, 150 mmol/L NaCl, 5 mmol/L EDTA, 0.5% sodium deoxycholate, and 0.1 mmol/L phenylmethylsulfonyl fluoride) with a Dounce homogenizer, and the lysate was centrifuged at 10,000 x g for 1 h. The supernatant was applied to an HSP27-N1 antibody affinity column, and the column was washed with lysis buffer. HSP27 was eluted by peptide antigen (10 mg/mL) for the HSP27-N1 antibody. The eluate was further applied to an HSP27-C1 antibody affinity column, and the column was washed with lysis buffer. HSP27 was eluted by a 10-mg/mL excess amount of HSP27-C1 antibody peptide antigen. HSP27 was separated from the peptide with Amicon Ultra-10 centrifugal filter units (Millipore, Billerica, MA, USA). The purity of the hHSP27 protein was over 95%. The investigation conforms to the principles outlined in the Declaration of Helsinki, and was reviewed and approved by the Juntendo University Ethics Committee. Written informed consent was obtained from all participants.

MS/MS Identification of hHSP27

hHSP27 was separated by native or SDS-polyacrylamide gel electrophoresis (PAGE). Proteins were stained with Coomassie Brilliant Blue. For protein spot analysis, including MS (Mass Spectrometry)/MS and MASCOT search analysis, we used the technical services of ProPhoenix Co., Ltd. (Hiroshima, Japan).

Experimental Protocol

Animal procedures were approved by the Animal Care Committee of Juntendo University. Eight-week-old adult male C57BL/6 mice weighing 20–23 g were housed under controlled lighting and provided food and water ad libitum. Mice were subjected to transient, 1-h MCAO, and then randomly divided into 3 groups: (1) an hHSP27 group that received tail-vein injections of hHSP27 after reperfusion, (2) a control group that received intravenous injections of 50 μg of bovine serum albumin (BSA), and (3) a sham-operated group that underwent the same procedure without MCAO. During this procedure, body temperature was maintained at 37±0.5°C with a heating pad. Systolic blood pressure was monitored by a noninvasive tail-cuff system (Softron BP-90A NIBP, Softron Co., Ltd.) in conscious mice. The selected dose and schedule of hHSP27 treatments were based on preliminary experiments that used 5 or 50 μg/mouse hHSP27 administered 0 (immediately), 1, 3, or 6 h after reperfusion (n = 3 in each group). Regional cerebral blood flow was measured by laser Doppler flowmetry before, during, and after MCAO, and before the mice were sacrificed. 24 h after reperfusion, mice were anesthetized by intraperitoneal injections of 50 mg/kg pentobarbital and decapitated. To evaluate infarct area and volume, brain slices were stained with cresyl violet or 2,3,5-triphenyltetrazolium chloride, scanned with AxioVision software (Carl Zeiss MicroImaging GmbH), and measured using the ImageJ program (NIH, http://rsb.info.nih.gov/ij/image/) [25].

Neurological Evaluation

Neurological functions were evaluated by the following modified scoring system: 0, no observable neurological deficits (normal); 1, failure to extend forepaw when entire body is lifted by tail (mild); 2, circling to contralateral side (moderate); and 3, loss of walking or righting reflex (severe) [26]. Three mice were tested in each group, and each mouse was subjected to 3 rounds of each test. The observers of the behavioral tests were blinded to the treatment groups, and mice of the various groups were randomized during a given testing period.

hHSP27 and HSP27 Antibody, HSP27 Elution Peptide Administration or Recombinant HSP27 Administration

Mice received intravenous injections of 50 μg of hHSP27 mixed with 50 or 500 μg of HSP27-N1 or -C1 antibody 1 h after reperfusion (n = 3 in each group), 5 or 50 μg of HSP27-N1 and -C1 peptides, which were used in the elution, intravenously 1 h after reperfusion (n = 3 in each group), or 50 μg of recombinant HSP27 (Acris Antibodies GmbH) 1 h after reperfusion (n = 3).

Dephosphorylated hHSP27 Administration

hHSP27 was dephosphorylated by active recombinant protein phosphatase 2A (Millipore) [16]. Mice received intravenous injections of 50 μg of dephosphorylated hHSP27 1 h after reperfusion (n = 3).

Identification of Transition in Brain Parenchyma by Intravenous hHSP27 Injection

hHSP27 was conjugated with fluorescein isothiocyanate (FITC) according to the manufacturer’s protocol (KPL, Inc.). Mice were administered 50 μg of FITC-hHSP27 intravenously 1 h after reperfusion and anesthetized with pentobarbital 30 min after the injection. Their brains were immediately removed, soaked in Tissue-Tek OCT Compound (SAKURA, Netherland), and frozen on liquid nitrogen. Coronal sections (20 μm) were cut on a cryostat (CM 1900, Leica Biosystems Nussloch GmbH, Nussloch, Germany). The sections were immediately, or after incubation with Alexa Fluor® 555 Conjugated anti-NeuN antibody (Millipore), mounted with Vectashield mounting medium (Vector
Laboratories, Inc., Burlingame, CA, USA). The sections were examined with an LSM 510 confocal laser scanning microscope (Carl Zeiss MicroImaging GmbH).

TUNEL Assay

For in situ DNA fragmentation detection, terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick-end labeling (TUNEL) was carried out with an in situ cell death detection kit (TMR Red, Roche Diagnostics GmbH) [27].

Fractionation of Mouse Brain

Twenty-four hours after reperfusion, a brain sample was harvested from ischemic regions of the cortex and striatum on the operated side of each mouse and placed in ice-cold synaptosome homogenizing buffer (320 mmol/L sucrose, 4 mmol/L HEPES, pH 7.4) with Complete Mini, EDTA-free, and phosphatase inhibitor cocktails I and II (Sigma-Aldrich Co.). Tissues were homogenized with a glass-Teflon homogenizer (12 up/down strokes, 900 rpm). The homogenized sample was centrifuged at 3,000 ×g for 5 min (step 1), and the supernatant was centrifuged at 12,000 ×g for 10 min (step 2). The resulting pellet was resuspended in isolation media and centrifuged at 3,000 ×g for 5 min to remove nuclear contamination (step 3). The supernatant from step 3 was centrifuged at 12,000 ×g for 10 min (step 4). Steps 3 and 4 were repeated twice to further purify the mitochondrial fraction. The resulting pellet from the 12,000 ×g spin was the mitochondria-enriched fraction. The supernatant obtained from step 2 was centrifuged at 70,000 ×g for 60 min (step 5). The resulting supernatant was the soluble cytosolic fraction. The pellet fractions were resuspended in isolation media. The purity of the fractions was tested by immunoblotting with a rabbit Tom20 antibody (mitochondrial marker; 1:5,000; Santa Cruz Biotechnology, Inc.), mouse anti-4-hydroxy-2-hexenal (HHE; 1:100; Japan), mouse anti-8-hydroxydeoxyguanosine (8-OHdG; 1:100; Japan Institute for the Control of Aging, Shizuoka, Japan), mouse anti-β-actin (1:200; Cell Signaling Technology, Inc.), rabbit anti-cleaved caspase-3 (1:200; Cell Signaling Technology, Inc.), and rabbit anti-cleaved caspase-9 (1:50; Cell Signaling Technology, Inc.).

Immunohistochemistry

Immunohistochemistry was performed on 20-μm free-floating sections. Sections were stained overnight using HSP27 C-1, rabbit anti-cytochrome c (1:100; Cell Signaling Technology, Inc., Beverly, MA, USA), rabbit anti-cleaved caspase-9 (1:50; Cell Signaling Technology, Inc.), rabbit anti-cleaved caspase-3 (1:200; Cell Signaling Technology, Inc.), mouse anti-β-actin (1:200; Cell Signaling Technology, Inc.), mouse anti-β-2-microglobulin (1:10,000; Millipore), mouse anti-β-actin (1:200; Cell Signaling Technology, Inc.), and rabbit anti-cytochrome c antibody (1:1,000). The sections were incubated with avidin-biotinylated peroxidase complex (Vector Laboratories, Inc., Burlingame, CA, USA) antibodies. Sections were then incubated with biotinylated secondary antibodies (1:300; Vector Laboratories, Inc.) and reacted with horseradish peroxidase-conjugated secondary antibody (1:5,000; GE Healthcare Life Sciences, Buckinghamshire, UK). Immunoreactive bands were visualized with an enhanced chemiluminescence kit (GE Healthcare Life Sciences). Protein loading of lanes was assessed with α-tubulin immunoreactivity (53 kDa).

Cell Counts

In the immunohistochemical analyses, positively stained cells in the ischemic boundary zone (IBZ) adjacent to the ischemic core (0.25 mm²) were counted in 5 sections from each of 3 mice were counted using AxioVision by an investigator who was blinded to the experimental groups. All values are expressed as mean ± SEM.

Statistical Analysis

One-way analysis of variance and Fisher’s exact test protected least significant difference tests were used to determine the significance of differences between the groups. P values less than 0.05 indicated statistical significance.

Results

Purification of Human HSP27

To examine the effects of HSP27 on ischemic injury, we initially injected recombinant HSP27 (rHSP27) into ischemic model mice, but did not observe any infarct suppression (data not shown). Because rHSP27 is not phosphorylated and occurs in large oligomers, we decided to use human physiological HSP27 for subsequent studies because it is phosphorylated (at S15, S78, and S82) and reorganizes into large oligomers into dimers, trimers, and multimers in response to many insults and interacts with other small HSPs [7]. To obtain physiological HSP27, we purified HSP27 from human lymphocytes (hHSP27) with 2 human-specific HSP27-antibody affinity columns. The resulting protein purity was more than 95% (Figure 1A). We found more dimeric, trimeric, and multimeric configurations and fewer large oligomers of hHSP27 than those of rHSP27 (Figure 1B), and increased phosphorylation (Figure 1C). A mass spectrometric analysis revealed that a high molecular weight hHSP27 multimer contained HSP27 and α-crystallin and HSP20. We also identified the peptides, RVPFSLLRGSWDPRFDWVYPHSRLFDQAFGLPR, VSLDVHAFAPDELTVK, KYTLPQPVDQTVSSSL-SPEGTLTVAPMPK, LATQSNITIPVTFSR, and AQILGG-PEAASDETAAK, which are consistent with the HSP27 protein (GenBank, NCBI, CA). The most frequently used SDS gel was a 4–12% gradient gel. Native-PAGE experiments were performed with the NativePAGE Novex Bis-Tris Gel System according to the manufacturer’s instructions. The most frequently used native gel was a 4–16% gradient gel. To this solution, an additional detergent to be tested was added at a final concentration of 0.4% [1,0% in the case of n-octyl-β-D-glucoside (β-OG)] and incubated for 10 min prior to blue native–PAGE. To each lane of a native gel, 3–5 μg of protein were loaded. Anode buffer was made by diluting the 20x NativePAGE running buffer (Invitrogen, Carlsbad, CA), and the cathode buffer by mixing the NativePAGE running buffer with Cathode Buffer additive (Gomassie Blue G-250 dye, Invitrogen) according to the manufacturer’s instructions. For BN–PAGE with membrane proteins, the concentration of the blue dye was 0.02% (w/v), which is tenfold higher than that for soluble proteins. The gel was stained using the Colloidal Blue Staining Kit (Invitrogen). Block Ace (Daichi Kogyo Seiyaku, Co., Ltd., Gifu, Japan) or PBS containing 0.05% Tween-20 (Sigma-Aldrich Co.) was used for blocking. Membranes with transferred proteins were incubated overnight with antibodies against HHF (1:1,000; Cosmo Bio Co., Ltd Carlsbad CA), and reacted with horseradish peroxidase-conjugated secondary antibody (1:5,000; GE Healthcare Life Sciences, Buckinghamshire, UK). Immunoreactive bands were visualized with an enhanced chemiluminescence kit (GE Healthcare Life Sciences). Protein loading of lanes was assessed with α-tubulin immunoreactivity (53 kDa).
sequence (gi662841); MDIAIHHPWIR, RPFFPFHSPSR, APSWFDYLSEMIR and IPADVDPITTSLSLSDGVTVNGPR, which are consistent with the αβ-crystallin protein sequence (gi2845682); and MEIPVPVQPSWLR and HEERPDEHGFVAR, which are consistent with the HSP20 protein sequence (gi2477511). The hHSP27 dimer and tetramer contained only HSP27 without αβ-crystallin and HSP20. Immuno-

blot analysis revealed that the high molecular weight hHSP27 multimer contained αβ-crystallin and HSP20 (Figure 1D). Both immunoblot and mass spectrometric analyses (data not shown) revealed that hHSP27 contained only HSP27 and not αβ-crystallin and HSP20 (Figure 1E). Both immunoblot and mass spectrometric analyses (data not shown) revealed that rHSP27 contained only HSP27 and not αβ-crystallin and HSP20. Ten nanograms of hHSP27 contained less than 0.5 ng each of αβ-crystallin and HSP20, that is, the amount of HSP27 contained in the hHSP27 was more than 20 times that of αβ-crystallin and HSP20 (Figure 1E). The amounts of αβ-crystallin and HSP20 were determined by comparing them with known amounts of their respective commercial recombinant proteins. We also chose to use hHSP27 in subsequent studies, because hHSP27 subjected to various physiological posttranslational modifications may influence function.

hHSP27 Attenuates Ischemic Brain Damage

The HSP27 treatment protocol was first determined in preliminary experiments. Ischemic mice (see Methods) were intravenously injected with either hHSP27 (5 or 50 μg) or BSA (50 μg) 0, 1, 3, or 6 h after reperfusion (Figure 2A), and infarct volumes were measured in cresyl violet-stained sections made 24 h after reperfusion (Figure 2B). Infarct volume was reduced by 37% in mice treated 0 h after reperfusion with 5 μg of hHSP27 (19.49±1.12 mm³, P<0.001, n = 5) and by 61% in those treated with 50 μg of hHSP27 (12.39±0.73 mm³, P<0.001, n = 5) vs. BSA-treated controls (31.55±1.28 mm³; n = 5, Figure 2B,C). Infarct volume tended to be reduced more when the 50-μg dose was administered 1 h after reperfusion (63% reduction; 11.71±1.36 mm³, P<0.001, n = 5); there was only a slight reduction at 3 h and no difference at 6 h after reperfusion vs. controls (Figure 2C). The hHSP27 group showed better functional recoveries [hHSP27 (0 h): P=0.004, hHSP27 (1 h): P=0.004] than controls (Figure 2D). There was no difference in regional cerebral blood flow between the treated and control groups (Figure 2E). Based on these findings, in the remaining experiments, we injected 50 μg of hHSP27 1 h after reperfusion because it was most effective in reducing infarct volume (Figure 2F).

To exclude the possibility that molecules co-purified with HSP27, such as αβ-crystallin and HSP20, attenuated ischemic brain damage, we administered hHSP27 in the presence of HSP27-N1 and -C1 antibodies or HSP27-elution peptides (HSP27-N1 and -C1 peptides), instead of HSP27. The co-administration of hHSP27 and HSP27 antibody (50 μg hHSP27 and 50 μg HSP27 antibodies: 26.28±0.93 mm³ n = 3; 50 μg hHSP27 and 500 μg HSP27 antibodies: 29.79±0.93 mm³ n = 3) resulted in infarct volumes that were not significantly different from control (Figure 3A). The HSP27 antibody inhibited the protective effects of hHSP27, indicating hHSP27 as the source of cellular protection and not other co-purified molecules. The administration of HSP27 elution peptides had no effect on ischemic brain damage (Figure 4A).

Nonphosphorylated rHSP27 purified from Escherichia coli also did not reduce infarct volume (50 μg rHSP27:31.41±0.27 mm³; 16.43±0.69 mm³ P<0.001, n = 3) vs. controls (38.09±0.24 mm³ n = 3) (Figure 3A,B,C).
HSP27 Protects against Ischemic Brain Injury

A. Diagram of MCAO, Reperfusion, and Sacrifice timelines with hHSP27 injection.

B. Images showing control and hHSP27 5µg 0h.

C. Graph showing intact volume (mm³) with different doses (µg) and schedules (hour).

D. Graph showing neurological deficit score over time after reperfusion.

E. Graph showing rCBF (%) over time after reperfusion.

F. Images showing control and hHSP27 50µg 1h.
Figure 2. hHSP27 attenuates ischemic brain damage. A, Schematic of hHSP27 injection schedules for determining the HSP27 treatment protocol. B, Photomicrographs of cresyl violet-stained infarcts in controls, the 5-µg hHSP27 group (0 h), 50-µg hHSP27 group (0 h), and 50-µg hHSP27 group (1 h), 24 h after reperfusion. Infarct areas are circumscribed with dotted lines. Scale bar = 1 mm. C, Infarct volumes at various doses (given at 0 h) and schedules (50 µg doses) of hHSP27. D, Neurological deficit scores in controls, the 50-µg hHSP27 group (0 h), and the 50-µg hHSP27 group (1 h) immediately (Post) and 24 h following reperfusion. E, Temporal changes in regional cerebral blood flow (rCBF), before (Pre), during, and 24 h after MCAO. F, Photomicrographs of infarct areas stained with 2,3,5-triphenyltetrazolium chloride in controls and the 50-µg hHSP27 group (1 h) 24 h after reperfusion. Data are presented as mean ± SEM of 3 mice (8, B, E) and 5 mice (D) in each group. *P < 0.05, **P < 0.001 vs. controls. hHSP27, human heat shock protein; MCAO, middle cerebral artery occlusion.

doi:10.1371/journal.pone.0066001.g002

Localization of (FITC)-hHSP27 in Brain Parenchyma after Injection

To obtain direct evidence of hHSP27 localization in brain, we injected fluorescein isothiocyanate (FITC)-hHSP27. To preserve the FITC-hHSP27 signal, we made fresh frozen sections. FITC-hHSP27 was diffusely localized in brain (Fig. 5A, B). FITC-hHSP27 also localized in neuronal marker protein NeuN-positive cells (Figure 5C–H), indicating that FITC-hHSP27 was localized in neurons. FITC-hHSP27 was also localized in NeuN-negative cells. We found larger amounts of FITC-HSP27 on the ischemic side than on the non-ischemic side of brain.

hHSP27 Suppresses Apoptotic Cell Death, Oxidative DNA Damage, Lipid Peroxidation and Glial Activation

The numbers of cells immunopositive for cytochrome c, cleaved caspase-9, and cleaved caspase-3, and the number of terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick-end labeling (TUNEL)-positive cells 24 h after reperfusion were significantly lower (P = 0.00024) in the hHSP27 group than in the controls (Figure 6A, B). Cytochrome c levels (15 kDa) in cytosolic fractions were also significantly lower (P = 0.00016) in the hHSP27 group vs. controls (Figure 6C, D). Because expansion of the damaged area following an ischemic insult has been attributed to immediate and direct cytotoxic effects of oxidative products [28,29], we examined the effects of hHSP27 on levels of 8-hydroxydeoxyguanosine (8-OHdG), an oxidized nucleoside of DNA, and 4-hydroxy-2-hexenal (HHE), a major lipid peroxidation product. The numbers of cells immunopositive for these oxidative stress markers 24 h after reperfusion were significantly lower (P < 0.001) in the hHSP27 group vs. controls (Figure 7A, B). The numbers of ionized calcium-binding adapter molecule-1 (Iba-1)-positive activated microglia and astrocytes 24 h after reperfusion, were also significantly lower (P < 0.001) in the hHSP27 group vs. controls (Figure 7A, B).

Discussion

In our experiments, delayed intravenous injections of phosphorylated, multimeric hHSP27 complexes following reperfusion after transient MCAO reduced infarct volume, neurological deficits, and apoptotic cell death, and at the same time decreased TUNEL reactions and the levels of cytochrome c, cleaved caspase-9, and cleaved caspase-3. The hHSP27 complex also decreased oxidative DNA damage, lipid peroxidation, and glial activation. Thus, hHSP27 appears to protect brain by inhibiting apoptosis and oxidative stress following ischemia and reperfusion. We also confirmed that it was the HSP27 that protected the brain, as a specific anti-HSP27 antibody inhibited the protective effects.

Figure 3. Neuroprotective effects of hHSP27 against ischemic/reperfusion injury 72 h after reperfusion. A, Photomicrographs of infarct areas stained with cresyl violet in control and hHSP27 groups 72 h after reperfusion. Infarct areas are circumscribed with dotted lines. Scale bar = 1 mm. B, Infarct volumes in control and hHSP27 groups. C, Neurological deficit scores in control and hHSP27 groups. Data are presented as mean ± SEM of 3 mice (B) and 5 mice (C) in each group. *P < 0.05, **P < 0.001 vs. controls.

doi:10.1371/journal.pone.0066001.g003
Administered hHSP27 crossed the blood-brain barrier injured by ischemic insults and was localized in neurons on the ischemic side of brains, where it prevented apoptosis and oxidative stress and thereby neuronal death.

The more physiological hHSP27 (i.e., the phosphorylated multimeric complex) and not rHSP27 protected ischemic brains against damage. HSP27 tends to form variable-sized oligomers [30–32], depending on posttranslational modifications. Phosphorylation leads to the formation of small oligomers [30,31,33], monomers, and dimers [34,35], which act as molecular chaperones, interfere with caspase activation, modulate oxidative stress, and regulate the cytoskeleton [7]. hHSP27 formed more dimers,
Figure 5. Localization of injected FITC-hHSP27 on the ischemic and non-ischemic sides of mouse brain. A–H, FITC-hHSP27 (green, A,B); NeuN, a neuronal marker protein (red, C,D); merge (E–H), FITC, fluorescein isothiocyanate. Scale bar = 100 um.
doi:10.1371/journal.pone.0066001.g005

Figure 6. Effects of hHSP27 on cell death. A, Photomicrographs of anti-cytochrome c, anti-cleaved caspase-9, anti-cleaved caspase-3, and TUNEL staining in the infarct boundary zones in controls and the hHSP27-treated group prepared 24 h after reperfusion. Scale bars = 50 um. B, Number of cytochrome c-, cleaved caspase-9-, cleaved caspase-3-, and TUNEL-positive cells. C, Immunoblots of cytochrome c, Tom20 (mitochondrial marker), and actin, 24 h after reperfusion. D, Densitometric analysis of cytochrome c protein in cytosolic fractions of isolated hHSP27. Data are means±SEM (B,D). **P<0.001 vs. controls. TUNEL, terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick-end labeling; hHSP27, human heat shock protein.
doi:10.1371/journal.pone.0066001.g006
Dephosphorylation of hHSP27 increased the large oligomers and decreased the dimers, tetramers, and multimers, resulting in a loss of its protective effects. Phosphorylation may be a key factor in brain protection. Our results suggested that the injection of phosphorylated dimeric, tetrameric, and multimeric hHSP27 was important for brain protection in our model of ischemia/reperfusion. We speculated that intravenously injected hHSP27 may not only increase the concentration of endogenous HSP25, which is the mouse homolog of HSP27, but also may have a novel exposure effect to the neurons. hHSP27 was also localized in extracellular space in brain, and usually the concentration of HSP27 was very low in the extracellular space. Further studies will be needed to ascertain the mechanisms by which intravenously injected hHSP27 provides neuronal cell protection.

Isolated hHSP27 also contained small amounts of αB-crystalline and HSP20, which were part of high molecular weight HSP27 oligomers. Because they were co-purified with antibodies specific for HSP27 suggests that they were not simple contaminations, but that they interact with HSP27 in a sort of hHSP27 complex.
Previous studies showed that because of similarity in structure and properties, HSP27, β-crystallin, and HSP20 are co-purified [36]; thus, the possibility exists that the β-crystallin and HSP20, which are part of the hHSP27 complex, may influence the effects of brain protection. We showed, however, that co-administration of hHSP27 with the presence of a specific anti-HSP27 antibody decreased the ability of hHSP27 to protect the brain against ischemic injury, strongly suggesting that most of the brain protective effect of HSP27 was caused by hHSP27. The necessary modifications of rHSP27, including phosphorylation and interaction with β-crystalline and HSP20, to mimic hHSP27 in ischemic brain treatment need to be identified.

The blood brain barrier (BBB) controls the passage of substances from the blood into the CNS [37]. Usually, injected proteins are hampered from reaching brain neurons by the tight regulation of the BBB. We observed peripherally injected FITC-HSP27 in neurons, indicating that FITC-HSP27 crossed the BBB and then entered neurons. Increased numbers of FITC-labeled positive neurons on the ischemic side of the brain compared to the non-ischemic side suggests that the injured BBB enabled the FITC-hHSP27 to pass. Further studies are needed to elucidate the mechanism by which hHSP27 crosses the injured BBB and enters neurons.

HSP27 was shown to attenuate ischemic brain damage in transgenic mice overexpressing HSP27 [18,38] and when it was delivered via viral HSP27 expression vectors [20,39] or injected as the PEP-1-HSP27 protein [40]. There are, however, some differences between our study and the PEP-1-HSP27 study. An et al. used a delayed mouse model of neuronal cell death, a special ischemic model, whereby delayed neuronal death, caused by a very short 5-min artery occlusion, is mainly observed only in the hippocampus, and PEP-1-HSP27 was injected before the ischemic insult. By contrast, we used the more usual MCAO model of ischemia and administered hHSP27 after the ischemic insult, which is closer to the treatment paradigm that patients with ischemic stroke would experience. Ischemic damage was suppressed by the delayed, intravenous administration of hHSP27 after MCAO, as it would be administered to patients with brain infarctions. Although a delay of 1 h was more effective than 3 h, which would be difficult to accomplish in ischemic stroke patients, the necessary administration times may be different in human patients than in mice. Administering HSP27 viral vectors to patients may be dangerous, because HSP27 levels are significantly increased in many tumors [41,42,43,44] and increased HSP27 expression correlates with increased resistance to cytotoxic (antineoplastic) compounds [41,42,43].

Because hHSP27 was purified from human tissues, the HSP27 effects in humans should not be affected by interspecies influences. Hence, hHSP27 has potential as a medical intervention to suppress cell death in ischemic stroke patients. We propose that delayed injection of human-derived HSP27 may salvage brain tissue and improve function following cerebral ischemia as well as other vascular diseases, such as cardiovascular disease. In the future, we intend to purify hHSP27 from a patient with acute stroke and subsequently inject the hHSP27 solution into the patient.

Author Contributions
Conceived and designed the experiments: ST HS RT HA TU NH. Performed the experiments: ST HS YS NM. Analyzed the data: ST HS RT YS. Contributed reagents/materials/analysis tools: ST HS RT YS. Wrote the paper: ST HS NH.

References
1. Ginsberg MD (2008) Neuroprotection for ischemic stroke: past, present and future. Neuropharmacology 55: 363–389.
2. Phan TG, Wright PM, Markus R, Howells DW, Davis SM, et al. (2002) Salvaging the ischaemic penumbra: more than just reperfusion? Clin Exp Pharmacol Physiol 29: 1–10.
3. O’Collins VE, Macleod MR, Donnan GA, Horky LL, van der Worp BH, et al. (2006) 1,026 experimental treatments in acute stroke. Ann Neurol 59: 467–477.
4. Faden AI, Stoica B (2007) Neuroprotection: challenges and opportunities. Arch Neurol 64: 794–800.
5. Warner DS, Sheng H, Batinec-Habere I (2004) Oxidants, antioxidants and the ischemic brain. J Exp Biol 207: 3221–3231.
6. Andradi SA, Sayerd I, Siemen D, Wolf G, Horn TF (2004) Direct inhibition of the mitochondrial permeability transition pore: a possible mechanism responsible for anti-apoptotic effects of melatonin. FASEB J 18: 869–871.
7. Concannon CG, Gorman AM, Samali A (2003) On the role of Hsp27 in regulating apoptosis. Apoptosis 8: 61–70.
8. Bukach CV, Gluhkova AE, Seiti-Nebi AS, Gueve NB (2009) Heteroerogliomecomplexes formed by human small heat shock proteins HspB1 (Hsp27) and HspB6 (Hsp20). Biochim Biophys Acta 1794: 496–495.
9. Strede RA, Gao Y, Signore AP, Cao G, Chen J (2009) HSP27: mechanisms of cellular protection against neuronal injury. Curr Mol Med 9: 863–872.
10. Strede RA, Gao Y, Zhang W, Liu AK, Gao Y, et al. (2010) Heat shock proteins: cellular and molecular mechanisms in the central nervous system. Prog Neurobiol 92: 184–211.
11. Ethlymous CA, Mocanu MM, de Belleruche J, Wells DJ, Latchmann DS, et al. (2004) Heat shock protein 27 protects the heart against myocardial infarction. Basic Res Cardiol 99: 392–394.
12. Hollander JM, Martin DJ, Belke DD, Scott BT, Swanson E, et al. (2004) Overexpression of wild-type jejunum shok protein 27 and a nonphosphorylatable heat shock protein 27 mutant protects against ischemia/reperfusion injury in a transgenic mouse model. Circulation 110: 3544–3552.
13. Akbar MT, Landberg AM, Liu K, Veligudaran S, Wells KE, et al. (2003) The neuroprotective effects of heat shock protein 27 overexpression in transgenic animals against kainate-induced seizures and hippocampal cell death. J Biol Chem 278: 19956–19960.
14. Sharp P, Krishnan M, Pullar O, Navarrete R, Wells D, et al. (2006) Heat shock protein 27 rescues motor neurons following nerve injury and preserves muscle function. Exp Neurol 198: 511–518.
15. Abisambra JF, Blair L, Hill SE, Jones JR, Kraft C, et al. (2010) Phosphorylation dynamics regulate Hsp27-mediated rescue of neuronal plasticity deficits in tau transgenic mice. J Neurosci 30: 15374–15382.
16. Shimura H, Musa-Shimura Y, Kosik KS (2004) Binding of tau to heat shock protein 27 leads to decreased concentration of hyperphosphorylated tau and enhanced cell survival. J Biol Chem 279: 17957–17962.
17. Sharp PS, Akhtar MT, Bouri S, Senda A, Yoshitani K, et al. (2008) Protective effects of heat shock protein 27 in a model of ALS occur in the early stages of disease progression. Neurobiol Dis 30: 42–55.
18. Strede RA, Cao G, Gao Y, Zhang W, Wang S, et al. (2008) Hsp27 protects against ischemic brain injury via attenuation of a novel stress-response cascade upstream of mitochondrial cell death signaling. J Neurosci 28: 13038–13055.
19. Badin RA, Lythgoe MF, van der Werf L, Thomas DL, Gadian DG, et al. (2006) Neuroprotective effects of virally delivered HSP27 in experimental stroke. J Cereb Blood Flow Metab 26: 371–381.
20. Badin RA, Modo M, Cheetham M, Thomas DL, Gadian DG, et al. (2009) Protective effect of post-ischaemic viral delivery of heat shock proteins in vivo. J Cereb Blood Flow Metab 29: 254–263.
21. Kato H, Araki T, Itoyama Y, Kogure K, Kato K (1995) An immunohistochemical study of heat shock protein-27 in the hippocampus in a gerbil model of cerebral ischemia and ischemic tolerance. Neuroscience 68: 65–71.
22. Currie RW, Ellison JA, White RF, Feuerstein GZ, Wang X, et al. (2000) Benign endogenous mediators of preconditioning-induced ischemic tolerance in rat brain identified by genomic and proteomic analysis. J Neurochem 76: 73–89.
23. Strede RA, Gao Y, Zhang W, Dzeng Z, Zhang F, et al. (2012) Phosphorylation of HSP27 by protein kinase D is essential for mediating neuroprotection against ischemic neuronal injury. J Neurosci 32: 2667–2662.
27. Miyamoto N, Zhang N, Tanaka R, Liu M, Hattori N, et al. (2008) Neuroprotective role of angiotensin II type 2 receptor after transient focal ischemia in mice brain. Neurosci Res 61: 249–256.

28. Love S (1999) Oxidative stress in brain ischemia. Brain Pathol 9: 119–131.

29. Chan PH (2001) Reactive oxygen radicals in signaling and damage in the ischemic brain. J Cereb Blood Flow Metab 21: 2–14.

30. Rogalla T, Ehrmsperger M, Previle X, Kotlyarov A, Lutsch G, et al. (1999) Regulation of Hsp27 oligomerization, chaperone function, and protective activity against oxidative stress/tumor necrosis factor alpha by phosphorylation. J Biol Chem 274: 18947–18956.

31. Hayes D, Napoli V, Mazurkie A, Stafford WF, Graceffa P (2009) Phosphorylation dependence of hsp27 multimeric size and molecular chaperone function. J Biol Chem 284: 18001–18007.

32. Lambert H, Charrette SJ, Bernier AF, Guimond A, Landry J (1999) HSP27 multimerization mediated by phosphorylation-sensitive intermolecular interactions at the amino terminus. J Biol Chem 274: 9378–9385.

33. Kato K, Hasegawa K, Goto S, Inaguma Y (1994) Dissociation as a result of phosphorylation of an aggregated form of the small stress protein, hsp27. J Biol Chem 269: 11274–11278.

34. Lelj-Garolla B, Mauk AG (2005) Self-association of a small heat shock protein. J Mol Biol 345: 631–642.

35. Dudich IV, Zav’yalov VP, Pfeil W, Gaestel M, Zav’yalova GA, et al. (1995) Dimer structure as a minimum cooperative subunit of small heat-shock proteins. Biochim Biophys Acta 1253: 163–168.

36. Kato K, Goto S, Inaguma Y, Hasegawa K, Morihita R, et al. (1994) Purification and characterization of a 20kDa protein that is highly homologous to alpha B crystallin. J Biol Chem 269: 15302–15309.

37. Spencer BJ, Verma IM (2007) Targeted delivery of proteins across the blood-brain barrier. Proc Natl Acad Sci U S A 104: 7594–7599.

38. van der Weerd L, Tariq Akbar M, Aron Badin R, Valentinim LM, Thomas DL, et al. (2010) Overexpression of heat shock protein 27 reduces cortical damage after cerebral ischemia. J Cereb Blood Flow Metab 30: 849–856.

39. Wagstaff MJ, Collaco-Moraes Y, Smith J, de Bellercope JS, Coffin RS, et al. (1999) Protection of neuronal cells from apoptosis by Hsp27 delivered with a herpes simplex virus-based vector. J Biol Chem 274: 5061–5069.

40. An JJ, Lee YP, Kim SY, Lee SH, Lee MJ, et al. (2008) Transduced human PEP-1 heat shock protein 27 efficiently protects against brain ischemic insult. FEBS J 275: 1296–1308.

41. Assimakopoulou M, Sotiropoulou-Bonikou G, Maraziotis T, Varakis I (1997) Prognostic significance of Hsp-27 in astrocytic brain tumors: an immunohistochemical study. Anticancer Res 17: 2677–2682.

42. Ciocca DR, Calderwood SK (2005) Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications. Cell Stress Chaperones 10: 86–103.

43. Fuqua SA, Oesterreich S, Hilsenbeck SG, Von Hoff DD, Eckhardt J, et al. (1994) Heat shock proteins and drug resistance. Breast Cancer Res Treat 32: 67–71.

44. Huang Q, Ye J, Chen W, Wang L, Liu W, et al. (2010) Heat shock protein 27 is over-expressed in tumor tissues and increased in sera of patients with gastric adenocarcinoma. Clin Chem Lab Med 48: 263–269.

45. Vargas-Roig LM, Gago FE, Tello O, Aznar JC, Ciocca DR (1998) Heat shock protein expression and drug resistance in breast cancer patients treated with induction chemotherapy. Int J Cancer 79: 468–475.